DarioHealth Earnings Call Highlights Growth Amid Risks

DarioHealth ((DRIO)) has held its Q1 earnings call. Read on for the main highlights of the call.

DarioHealth’s latest earnings call struck a cautiously optimistic tone, as management balanced evidence of operational progress against lingering revenue and execution risks. They highlighted back‑to‑back quarters of sequential growth, sharply lower operating expenses and stronger unit economics, while acknowledging ongoing losses, limited visibility and uncertainty from an active strategic review.

Sequential Revenue Growth

DarioHealth reported Q1 2026 revenue of $5.6 million, up from $5.2 million in Q4 2025, marking roughly 7.7% quarter‑over‑quarter growth and a second straight sequential increase. Management framed this as early proof that its revamped business model is beginning to scale, even as overall revenue remains modest relative to the company’s long‑term ambitions.

Commercial Pipeline and Account Wins

The company underscored a robust commercial pipeline of about $127 million spread across 241 open opportunities, signaling considerable future revenue potential. It also exceeded its prior targets by adding 85 new accounts in 2025 and another 10 in Q1 2026, with most recent wins coming through channel partners rather than direct sales.

Channel Partnerships Expand Distribution Reach

DarioHealth’s channel ecosystem has become the centerpiece of its growth strategy, already providing access to more than 116 million covered lives. A newly signed, largest‑ever channel deal with a major Northeastern hospital network is expected to lift total distribution reach to over 175 million covered lives and add roughly 3,500 employer relationships.

High‑Margin B2B2C Economics

Gross margin reached 57% in Q1 2026, stable year‑over‑year and up from 54% in the prior quarter, as the mix shifts toward higher‑value solutions. The company’s core B2B2C business maintained a non‑GAAP gross margin of about 80% for the ninth consecutive quarter, highlighting attractive unit economics as channel revenue scales.

Operating Expense Cuts and Loss Improvement

Total operating expenses fell to $10.5 million in Q1 2026, a 21% decline year‑over‑year and 8% reduction sequentially, while non‑GAAP OpEx dropped to $8.7 million. These cuts helped improve the GAAP operating loss to $7.3 million and the non‑GAAP operating loss to $5.3 million, reflecting double‑digit percentage improvements versus both last year and last quarter.

Improved Cash Usage and Liquidity

The company ended March 2026 with $20 million in cash and short‑term deposits, providing some cushion as it pursues growth. Net cash used in operations fell to $6.0 million in Q1 from $6.7 million a year earlier, and management noted continued compliance with its debt covenants, with no principal repayments due until 2028.

Contracted Revenue and Late‑Stage ARR

Management pointed to nearly $13 million in contracted and late‑stage business finalized by the end of 2025 as a key near‑term growth driver. They also highlighted about $30 million in contracted annual recurring revenue embedded in late‑stage agreements that are slated to contribute to revenue starting later in 2026 and into 2027.

DarioIQ AI Drives Engagement Gains

The deployment of DarioIQ, the company’s AI‑driven engagement engine, is beginning to show tangible benefits in user behavior. Management cited internal data showing up to a 40% improvement in member retention and as much as a 55% lift in active sessions compared with control groups, suggesting AI could become a meaningful growth lever.

Data Assets and Clinical Evidence

DarioHealth emphasized its proprietary data moat, claiming more than 13 billion real‑world data points linked to clinical outcomes that feed its AI models. The company also referenced over 100 peer‑reviewed clinical studies supporting its solutions, positioning these assets as a competitive edge for personalization, regulatory credibility and outcomes‑based contracts.

Shift Toward Care Delivery Partnerships

A strategic pivot toward care‑adjacent partnerships is central to DarioHealth’s next phase, allowing it to participate more directly in care and outcomes without building a full provider network. One example is a deeper integration with GreenKey Health for a sleep apnea pathway, which could enable participation in claims‑ and outcomes‑based revenue streams.

Direct‑to‑Consumer Momentum

While the B2B2C business remains the primary growth engine, the company noted strong traction in its consumer segment, particularly in musculoskeletal products. Consumer revenue climbed 42% year‑over‑year and 24% sequentially in Q1, with management flagging growing international interest and uptake by clinics as additional demand drivers.

Intentional Year‑Over‑Year Revenue Decline

Despite sequential gains, overall revenue declined versus Q1 2025 as DarioHealth phased out non‑recurring pharmaceutical revenue that no longer fits its strategic focus. Management argued this deliberate reset should yield a more sustainable recurring revenue base over time, even though it pressures reported results in the near term.

Persistent Operating Losses

The company remains firmly in the red notwithstanding efficiency gains, with GAAP operating loss at $7.3 million and non‑GAAP at $5.3 million in Q1 2026. Management acknowledged that further cost discipline and scaled revenue from the pipeline will be needed before DarioHealth can approach breakeven and demonstrate a durable profit model.

Timing and Conversion Risk

A large share of the growth story depends on converting contracts signed in 2025 into live deployments and recognized revenue through 2026 and 2027. Management noted that onboarding, technical integrations and eligibility processes are underway but conceded that the exact timing and magnitude of revenue ramp‑up remain uncertain.

Reliance on Channels and Large Deployments

The increasing dependence on channel partners introduces concentration and execution risk, as growth now hinges on third‑party contracting cycles and implementation speed. Any delays or slower‑than‑expected rollouts by these partners could inject revenue volatility and dampen the benefits of the company’s expanding distribution footprint.

Limited Near‑Term Visibility and Strategic Review

DarioHealth declined to provide detailed revenue guidance for the second half of 2026 or specific ramp curves for new accounts, citing ongoing modeling efforts. At the same time, the company is pursuing a strategic review led by external advisers, a process that may unlock value but also adds uncertainty and potential distraction until a clear outcome emerges.

Investment Pace and Cash Constraints

While the $20 million cash balance and reduced burn extend the runway, management acknowledged that liquidity could constrain aggressive investment if revenue conversion lags. The company must balance funding growth initiatives, particularly around AI and partnerships, with preserving enough capital to navigate any delays in channel‑driven deployments.

Forward‑Looking Guidance

Looking ahead, management expects revenue to accelerate in the second half of 2026 as 2025‑signed accounts go live and add to top‑line growth. They pointed investors to the $127 million pipeline, roughly $30 million of contracted ARR in late‑stage agreements, expanding access to about 175 million covered lives and improving margins as evidence that the business is moving toward a more scalable, outcomes‑driven model.

DarioHealth’s earnings call painted the picture of a company in transition, tightening its cost structure while leaning into channels, AI and outcomes‑based partnerships to drive future growth. Investors are left weighing the attractive unit economics and expanding reach against ongoing losses, timing risks and strategic uncertainty that will need to resolve before the story fully rerates.